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Background: Dalteparin, a low-molecular-weight heparin, has anticoagulant and anti-angiogenic activity. This study
investigated whether dalteparin reduced coronary artery lesion (CAL) prevalence, and resistance to intravenous
immunoglobulin (IVIG) therapy in Kawasaki disease (KD).
Methods: This retrospective study comprised two parts. In the first cohort, 126 patients with KD (68 male, 58
female; median age: 22 months, range: 1–67 months) admitted to Nihon University Nerima-Hikarigaoka Hospital
from January 2004 to June 2008, received either dalteparin 75 IU/kg/day, IVIG 400 mg/kg/day for 5 consecutive
days, and aspirin 30 mg/kg/day, or dalteparin 75 IU/kg/day and aspirin 30 mg/kg/day, until clinical improvement.
Control data came from the 2005–6 Nationwide KD survey. In the second cohort, 112 patients with KD (59 male,
53 female; median age: 19 months, range: 1–66 months) admitted from June 2010 to February 2012, received
either dalteparin 75 IU/kg/day, IVIG 2.0 g/kg over 12 h, and aspirin 30 mg/kg/day, or dalteparin 75 IU/kg/day and
aspirin 30 mg/kg/day. Control data came from the 2009–10 Nationwide KD survey. No patients enrolled in the
nationwide surveys received dalteparin. All patients at our institution were given dalteparin in their combination
therapy.
Results: A comparison of the first cohort with controls in the nationwide survey showed that the prevalence of
initial administration of IVIG was 80.2% versus 86.0%; the rate of additional IVIG administration was 7.1% versus
14.0% (p = 0.03); CAL prevalence in the acute period was 4.8% versus 11.9% (p < 0.01); and the prevalence of
cardiovascular sequelae was 0% versus 3.8% (p < 0.05). A comparison of the second cohort with controls in the
nationwide survey showed that the rate of initial administration of IVIG was 92.9% versus 89.5%; the rate of
additional IVIG administration was 8.9% versus 17.1% (p = 0.02); the prevalence of resistance to IVIG was 3.6% versus
14.9% (p < 0.001); and CAL prevalence in the acute period was 2.7% versus 8.6% (p = 0.03).
Conclusions: This study found that adjunctive dalteparin was associated with a lower prevalence of IVIG
resistance and CAL in young children with KD.
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High-dose intravenous immunoglobulin (IVIG), together
with aspirin, is effective in resolving inflammation asso-
ciated with Kawasaki disease (KD). IVIG also effectively
reduces the occurrence of coronary artery lesions (CAL),
but these still occur in 12% of patients treated with low-
dose IVIG (400 mg/kg/day for 5 days) [1] and in 2.5% of
patients treated with high-dose IVIG (2 g/kg/day) [2].
The Japan Kawasaki Disease Research Committee con-
ducted the 21st Nationwide Survey of patients with KD
who visited target hospitals for the treatment of acute KD
during the 2-year period from January 2009 through
December 2010 [3]. The medical institutions included in
the survey were hospitals that specialized in pediatrics,
and hospitals that had a total of 100 or more beds and a
pediatric department.
Despite the effectiveness of IVIG treatment in reducing
cardiovascular complications in KD, between 5% and 10%
of treated patients develop CAL [3,4], which has led to the
search for more effective drugs for the treatment of KD.
Hence, we aimed to develop a more effective and safe regi-
men for the treatment of KD, regardless of the need for
any additional rescue treatment that might include corti-
costeroids or anti-cytokine drugs.
Vascular endothelial growth factor (VEGF) plays an
important role in maintaining vascular homeostasis.
Dysregulation of VEGF activity as well as that of other
angiopoietins contributes to the disruption of vascular
homeostasis in KD [5]. High VEGF levels have been de-
scribed in KD and have been implicated in the patho-
logical findings observed in vascular tissue in KD [6-9].
Dalteparin is a low-molecular-weight form of heparin
that inhibits both coagulation and angiogenesis, and is
safe and easy to use in clinical practice. Treatment with
dalteparin has been proposed to act by preserving endo-
thelial function through inhibition of the production
and activity of VEGF [10-12]. In Japan, dalteparin (75
units/kg/day continuous intravenous infusion) is recom-
mended for the treatment of disseminated intravascular
coagulation because it is associated with a lower bleeding
tendency than unfractionated heparin (p < 0.05, Level
2b evidence) [13]. However, the same indication for dalte-
parin is not recommended in other countries. Indeed,
dalteparin is only approved for intravenous use in
hemodialysis and hemofiltration procedures in Canada,
and not in the U.S.
Subcutaneous injection of dalteparin or enoxaparin is
also available for treating venous thromboembolism (VTE),
which is associated with heterozygous protein S or C defi-
ciency and is a major secondary complication in advanced
tertiary care of infants and children with critical illness.
Thus, optimal prophylactic and treatment strategies for
VTE are extremely important in children to avoid such
complications. Subcutaneous enoxaparin is also indicatedfor severe coronary artery disease requiring long-term sys-
temic anticoagulation after the acute phase of KD [14].
However, low-molecular-weight heparin, including enoxa-
parin and fondaparinux, is only available as a subcutaneous
injection, thus we chose dalteparin for continuous intraven-
ous infusion.
In the present study, patients with acute KD in our insti-
tution had initial treatment with a combination of dalte-
parin, aspirin, and/or IVIG. The aim of this retrospective
and pilot study was to investigate whether dalteparin in
the initial treatment phase is associated with a lower
prevalence of CAL in patients with acute KD.
Methods
Ethics statement
The study protocol conformed to the Declaration of
Helsinki and was approved by the Institute Review Board
of Nihon University Nerima-Hikarigaoka Hospital (NUNH
Hospital). All patients’ parents or guardians gave informed
consent for treatment with dalteparin, aspirin, and IVIG
(Figure 1). All clinical investigations were conducted ac-
cording to the principles expressed in the Declaration of
Helsinki.
Diagnosis
The diagnostic criteria were compliant with the Diagnostic
Guidelines for Kawasaki Disease (5th revision) [15].
Data collection
All KD patients admitted to the NUNH Hospital, at which
all authors formerly worked, were assigned initial treat-
ment according to the Harada score, which is frequently
used to predict increased risk of CAL before IVIG treat-
ment in Japan. The Harada score comprises the following
criteria: (1) white blood cell count > 12,000/mm3, (2) plate-
let count < 350,000/mm3, (3) C-reactive protein (CRP) con-
centration > 4.5 mg/dL, (4) hematocrit < 35%, (5) serum
albumin concentration < 3.5 mg/dL, (6) age < 12 months,
and (7) male sex. For KD patients with at least four of
these seven attributes, aspirin and IVIG therapy is typically
administered, and for patients with less than three attri-
butes, only aspirin is administered [16].
There are currently no guidelines in any country that
recommend withholding IVIG treatment in acute KD,
thus we conventionally adopted the Harada score protocol
whereby ASA alone is given to selected patients with KD
in Japan. ASA alone is generally not recommended in
acute KD, although the 19th and 21st Nationwide Surveys
reported that ASA alone was administered to 14.0% and
10.0%, respectively, of patients with KD in Japan (Tables 1
and 2). It is also noteworthy that the group assigned to
dalteparin and ASA alone in this study received non-
standard therapy that is not currently recommended in
any country, including Japan.






Figure 1 The two regimens of dalteparin combination therapy. *Aspirin (ASA) was decreased to 5 mg/kg/day if the patient was afebrile,
clinically improving, and/or showed a CRP < 1.0 mg/dL. **Aspirin withdrawn after 1 month of illness unless there were cardiac sequelae.
Dalteparin was administered until the patient was afebrile, clinically improving, and/or showed a CRP < 1.0 mg/dL. ***IVIG started on day 4 or 5 of
illness (the first illness day was defined as the day of onset of fever >38°C).
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with variations across both cohorts from 400 mg/kg/day
for 5 days, to 2 g/kg over 12 h for 1 day, or 1 g/kg over
12 h for 2 days.
The study design was retrospective and comprised two
parts. Subjects in the first cohort (n = 126 patients with
KD) were admitted to the NUNH Hospital between January
2004 and June 2008. The control data were sourced from
the 19th Nationwide Survey of KD performed from January
2005 through December 2006 [17]. The patients were
treated with either dalteparin at 75 IU/kg/day as a continu-
ous intravenous infusion until clinical improvement along
with low-dose IVIG (400 mg/kg/day for 5 consecutive days)
and aspirin at 30 mg/kg/day or a combination of dalteparin
and aspirin at the same doses. IVIG and dalteparinTable 1 Number and percentage of cases according to compo
Hospital in patients in the 19th Nationwide survey (2005–6) a
19th Nationwide survey (2005–200
Total 20,475 100.0
Dosage of IVIG Cases %
2 g/kg 11,612 56.7
1 g/kg/day × 2 d 4,800 23.4
400 mg/kg/day × 5 d 231 1.1
Various dosages of IVIG 879 4.3
Aspirin alone (no IVIG) 2,866 14.0
Dalteparin 0 0
Age (months) -*
Male sex 11,892 (58.1%)
KD: Kawasaki disease; NUNH Hospital: Nihon University Nerima-Hikarigaoka Hospita
Dalteparin was administered until the patient was afebrile, clinically improving, and
Data are median (range), n (%).
*The highest prevalence was observed among those aged 6–8 months [17].infusions were given simultaneously, with the patients re-
quiring a second intravenous access line for IVIG. The dose
of aspirin was decreased to 5 mg/kg/day if the patient was
afebrile, clinically improving, and/or had CRP < 1.0 mg/dL.
Dalteparin was administered until the patient was afebrile,
clinically improving, and/or had CRP < 1.0 mg/dL (Table 1).
Subjects in the second cohort (n = 112 patients with
KD) were admitted to NUNH Hospital between June 2010
and February 2012. Control data were sourced from the
21st Nationwide Survey of KD performed from January
2009 through December 2010. The patients were treated
with either dalteparin at 75 IU/kg/day as a continuous
intravenous infusion and high-dose IVIG (2 or 1 g/kg over
12 h for 1 or 2 days, respectively) and aspirin 30 mg/kg/
day or a combination of dalteparin and aspirin at the samenents of therapy in patients with KD at the NUNH
nd the first cohort (low-dose IVIG)











l; IVIG: intravenous immunoglobulin.
/or showed a C-reactive protein (CRP) < 1.0 mg/dL.
Table 2 Number and percentage of cases according to components of therapy in patients with KD at the NUNH
Hospital between the 21st Nationwide survey (2009–10) and the second cohort (high-dose IVIG)
21st Nationwide survey (2009–10) Second cohort (2010–12) p-value
Total 23,730 100.0 112 100.0
Dosage of IVIG Cases % Cases %
2 g/kg 17,547 74.0 85 75.9 0.75
1 g/kg/day × 2 d 2,803 11.8 5 4.5 0.01
400 mg/kg/day × 5 d 20 0.08 4 3.6 0.001
Various dosages of IVIG 868 3.65 0 0 0.04
Aspirin alone (no IVIG) 2,492 10.5 18 16.1 0.06
Dalteparin 0 0 112 100.0
Age (months) -* 19 (0–66)
Male sex 13,515 (57.0%) 59 (52.7%) 0.39
Dalteparin was administered until the patient was afebrile, clinically improving, and/or showed a CRP < 1.0 mg/dL.
Data are median (range), n (%).
*The prevalence was highest among children aged 6–11 months [3].
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eously, with the patients requiring a second intravenous
access line for IVIG. The aspirin dose was decreased to
5 mg/kg/day in patients who were afebrile, clinically im-
proving, and/or had a CRP < 1.0 mg/dL. Dalteparin was
administered until the patient was afebrile, clinically im-
proving, and/or had CRP < 1.0 mg/dL (Table 2).
A survey of CAL was performed using echocardiog-
raphy in all patients at follow-up, and within 3 months
of discharge. None of the patients were administered
corticosteroids. Although there was no information
about aspirin administration in the nationwide sur-
veys, we considered that aspirin was an anchor drug
and it was administered to all controls with KD. There
was no report of dalteparin administration in the na-
tionwide surveys and therefore it was assumed that
dalteparin was not administered to controls with KD.Definition of coronary artery lesions
The coronary arteries of patients were regularly assessed
by pediatricians using two-dimensional echography. Acute
cardiac lesions were defined as those that developed
within 1 month of onset (acute lesions); cardiac sequelae
were defined as those that persisted beyond 1 month after
onset [17].
We reviewed these records within 3 months from
the onset of KD. CAL was diagnosed in patients in ac-
cordance with the following Japanese Ministry of
Health criteria: an internal lumen diameter > 3.0 mm
in children < 5 years of age or > 4.0 mm in children ≥
5 years of age, an internal segment diameter at least
1.5 times larger than that of an adjacent segment, or
an irregular lumen [18]. Although some KD patients
present with CAL at diagnosis [19], we did not find
any cases before initial treatment in either cohort.Requirements for additional IVIG therapy
Additional IVIG therapy was provided when patients
had persistent fever > 38°C (axillary temperature) lasting
24 h after the completion of the initial treatment [20,21].
Resistance to IVIG therapy
Resistance of KD to IVIG was defined as the persistence
or recurrence of fever > 38°C (axillary temperature) at least
48 h after the end of the additional IVIG therapy [22].
Statistical analysis
We calculated the required sample size based on the as-
sumption that IVIG plus dalteparin would lower the
prevalence of acute-phase CAL from 12.0% to 4.0% (first
cohort) and from 9.0% to 2.0% (second cohort). With a
two-sided test, an α value of 0.05, a power of 80%, and a
total sample of 101 (first cohort) and 94 patients (second
cohort) would be needed.
Data are presented as a percentage for categorical vari-
ables. Baseline characteristics and components of treat-
ment were compared between the dalteparin group and
the control group using the chi-square test for categor-
ical variables. For all analyses, a two-sided p < 0.05 was
considered indicative of statistical significance. The odds
ratio was calculated as crude odds. The adjusted odds
ratio for dosage of initial IVIG therapy in both groups
was obtained using the Mantel-Haenstzel method, while
the adjusted odds ratio for acute-phase CAL, cardiac se-
quelae, and additional IVIG therapy was not analyzed
because the nationwide surveys contained no dosage in-
formation for the various initial IVIG treatments.
Coagulation parameters
Monitoring of prothrombin time and activated partial
thromboplastin time was not necessary. Monitoring of
dalteparin therapy is only possible using an anti-factor
Table 3 Comparison between the 19th Nationwide survey and the first cohort
19th Nationwide survey n; % First cohort group n; % p-value Odds ratio 95% CI
Total 20,475; 100.0 126; 100 (crude)
Initial IVIG therapy 17,613; 86.0 101; 80.2 0.06 0.91 0.53–1.57
0.38* 1.07* 0.88 – 1.30*
Acute phase CAL 2,446; 11.9 6; 4.8 < 0.01 2.71 1.19– 6.17
Cardiac sequelae 772; 3.8 0; 0 < 0.05 0 ‡NA
Additional IVIG therapy 2,860; 14.0 9; 7.1 0.03 2.08 1.06–4.13
CI: confidence interval; CAL: coronary artery lesions.
‡NA, unable to be calculated because the number contained “0.”
*Adjusted odds ratio for dosage of initial IVIG therapy in both groups was obtained using the Mantel-Haenstzel method adjusted for various initial dosages of
intravenous immunoglobulin (2 g/kg, 1 g/kg, 400 mg/kg, or various dosages of IVIG). Adjusted odds ratio for acute-phase CAL, cardiac sequelae, and additional
IVIG therapy were not analyzed because there were no descriptions of dosages of various initial IVIG in the nationwide surveys.
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fects in patients with severe renal dysfunction, abnormal
coagulation parameters, or bleeding. We did not moni-
tor anti-factor Xa levels in our cohort studies.
Results
Patient population
In the first cohort, there were 126 KD patients (68 male,
58 female; median age: 22 months, range: 1–167 months)
(Table 1). A total of 20,475 patients with KD (11,892
male, 8,583 female) were reported in the 19th Nation-
wide Survey, including 17,613 patients with initial IVIG
treatment, 2,860 patients with additional IVIG treat-
ment, 2,446 patients with CAL identified during the
acute phase of the disease, and 712 patients with cardiac
sequelae after 1 month from onset of KD. No subjects
who were enrolled in the nationwide surveys received
dalteparin. There were no data on patient characteristics,
demographics, and disease severity in the control popu-
lation [17], which is a limitation of this study.
In the second cohort, there were 112 KD patients (59
were male, 53 were female; median age: 19 months, range:
1–66 months) (Table 2). A total of 23,730 patients with
KD (13,515 were male, 10,215 were female) were reported
in the 21st Nationwide Survey, including 21,247 patients
with initial IVIG treatment, 4,049 patients with additionalTable 4 Comparison between the 21st Nationwide survey and
21st Nationwide survey n; % Secon
Total 23,730; 100.0
Initial IVIG therapy 21,247; 89.5
Acute phase CAL 2,044; 8.6
Cardiac sequelae 696; 2.9
Additional IVIG therapy 4,049; 17.1
Resistance for IVIG therapy 3,532; 14.9
*Adjusted odds ratio for dosage of initial IVIG therapy in both groups was obtained
intravenous immunoglobulin (2 g/kg, 1 g/kg, 400 mg/kg, or various dosages of IVIG
IVIG therapy were not analyzed because there were no descriptions of dosages of vIVIG treatment, 3,532 patients with resistance to IVIG,
2,034 patients with CAL who were identified during the
acute phase of disease, and 695 patients with cardiac se-
quelae after 1 month from onset of KD. No subjects who
were enrolled in the nationwide surveys received dalte-
parin. Again, there were no data on patient characteristics,
demographics, and disease severity in the survey [3].
Comparison between the first cohort and the 19th
nationwide survey
Initial IVIG therapy was used in 80.2% of patients in the
first cohort versus 86.0% in the survey (p = 0.06) (Table 3).
Additional IVIG therapy was used in 7.1% of patients in
the first cohort versus 14.0% in the survey (p = 0.027). The
occurrence of CAL in the first cohort was 4.8% versus
11.9% in the survey (p = 0.013), and cardiac sequelae oc-
curred in 0% versus 3.8% (p = 0.047) of patients. The rate
of resistance to IVIG therapy in the first cohort was 7.9%
but no information on IVIG resistance was reported in the
19th Nationwide Survey (Table 3). There were no adverse
events associated with dalteparin in the first cohort.
Comparison between the second cohort and 21st
nationwide survey
As shown in Table 4, initial IVIG therapy was adminis-
tered to 92.9% of patients in the second cohort versusthe second cohort
d cohort group n; % p-value Odds ratio 95% CI
112; 100.0 (crude)
104; 92.9 0.24 0.46 0.23–0.95
0.31* 1.20* 0.86–1.69*
3; 2.7 0.03 3.43 1.09–10.79
1; 0.9 0.32 3.35 0.47–24.06
10; 8.9 0.02 2.10 1.10–4.02
4; 3.6 < 0.001 5.16 1.09–14.00
using the Mantel-Haenstzel method adjusted for various initial dosages of
). Adjusted odds ratio for acute-phase CAL, cardiac sequelae, and additional
arious initial IVIG in the nationwide surveys.
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was given to 8.9% of patients in the second cohort versus
17.1% in the survey (p = 0.022). Similarly, the occurrence
of CAL in the second cohort was 2.7% versus 8.6% in the
survey (p = 0.025), and the occurrence of cardiac sequelae
was 0.89% versus 2.9% (p = 0.32). The rate of resistance to
IVIG therapy was 3.6% in the second cohort versus 14.9%
in the survey (p < 0.001) (Table 4). There were no adverse
events associated with dalteparin in the second cohort.
The occurrence of CAL, as well as the rate of add-
itional IVIG therapy and rate of resistance to IVIG ther-
apy in the second cohort group were markedly lower
than in the control group (Table 4).
Comparison between the first cohort and the
second cohort
There was a significant increase in the proportion of pa-
tients receiving initial IVIG therapy between the first
and second cohort groups (p < 0.005); but no other com-
parisons were not significantly different.
Discussion
Our cohorts showed reduced occurrence of acute-phase
CAL and cardiac sequelae compared with patients in ei-
ther nationwide survey. The occurrence of cardiac seque-
lae in patients on IVIG at 400 mg/kg/day for 5 days was
approximately 12%, whereas the occurrence in patients
given dalteparin in addition to IVIG at 400 mg/kg/day
for 5 days was 0%. An additional study has reported that
the occurrence of cardiac sequelae in patients on IVIG
at 2 g/kg/day was 2.5% [2].
The rate of resistance to IVIG therapy in KD in the
second cohort was markedly lower compared with that
reported in the 21st Nationwide Survey. Thus, the results
from the second cohort support the conclusion that dal-
teparin promotes the effectiveness of IVIG therapy in
acute KD. This suggests that dalteparin in combination
with IVIG may be more efficacious than IVIG alone.
The antiangiogenic activity of dalteparin, together with
its known anticoagulant activity provides the basis for
the beneficial clinical effects observed in KD. Moreover,
dalteparin therapy seems to be well tolerated and is not
associated with significant side effects [13].
Limitations
The present study at a single institution was limited by
its nonrandomized, retrospective nature. It should be
noted that such data might underestimate the true
prevalence of CAL, cardiac sequelae, and IVIG unre-
sponsiveness in patients with KD. Therefore, all poten-
tial sources of bias and confounders cannot be excluded
from any study. A further potential limitation of this
study was the use of the 19th and 21st Nationwide Sur-
veys for epidemiological control data because thesesurveys were not truly matched populations with respect
to our own cohorts. There were differences in the IVIG
dosing regimen between the first cohort and controls
(Table 1), but not between the second cohort and con-
trols (Table 2). In addition, the analysis did not account
for potential confounders, e.g., disease severity, age, sex,
fever, and laboratory data.
Other limitations include the non-standardized echo
readings without a core laboratory and single examiner,
and lack of laboratory studies to monitor anti-factor Xa
levels to support the safety of dalteparin in this setting.
In addition, we left the choice of dose of IVIG to each
doctor, and there may have been other unobserved or
unmeasured confounders associated with individualized
clinical decision-making.
Conclusions
This study found that concomitant dalteparin therapy
was associated with a lower prevalence of IVIG resist-
ance and CAL in KD. A multicenter randomized trial
should be performed to collect prospective data on KD
patients, and to further determine the efficacy of ad-
junctive therapy with dalteparin in KD patients.
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